| Name | Title | Contact Details |
|---|
JeNu Biosciences was founded by a leading Washington bio scientist and a medical technology entrepreneur. While working on an ultrasound device for topical drug delivery, they became curious about using ultrasound to improve cosmetic skin care product delivery. High energy ultrasound has been proven effective at pushing drugs through the skin, but in the process cells are damaged and high heat causes intense pain. But since cosmetics only need to be absorbed into the top layer of skin rather than through the skin like drugs they thought a low energy ultrasound device might work. After many attempts they proved that low energy ultrasound wouldn`t help on its own. At the same moment, they had the idea that lead to the JeNu System. Rather than using ultrasound energy to vibrate cells in the skin to open up pathways, what if they vibrated microspheres on the skin to open the pathways. This idea lead to patent application 20120271222 and JeNu Biosciences. Launched in 2009, JeNu spent close to $10MM and 5 years on research, development and engineering. JeNu Biosciences is now proud to present the JeNu System. It`s the first pain free, at home, quick way to increase absorption of your favorite skin care products. In just one minute per target area per day the JeNu system is clinically proven to increase absorption by up to 12 times, and improve the efficacy of skin care products by up to 40% in just 7 days.
Womens Specialty Care is a Macon, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Soft infotech is a Clifton, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
scPharmaceuticals, based in Lexington, MA, is a privately held biopharmaceutical company developing a portfolio of transformative pharmaceutical products for subcutaneous delivery. Based on widely used generic drugs that currently require intravenous or intramuscular injections, our innovative products will be administered subcutaneously via a proprietary patch pump. This avoids material risks and costs associated with the current delivery options. Our lead products are the first subcutaneous formulations of furosemide (the most widely used parenteral diuretic in treating heart failure) and ceftriaxone (the most widely used parenteral antibiotic outside the hospital setting). Our novel furosemide formulation enables convenient anytime anywhere use, for example in an outpatient setting instead of the emergency room or other in-patient settings. For ceftriaxone and other antibiotics, subcutaneous administration eliminates the need for PICCs (peripherally inserted central catheters), which are associated with serious complications, frequent adverse events and high medical cost. For further information on how we are transforming the administration of parenteral drugs.
Welch Healthcare and Retirement is a Norwell, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.